On the other hand, combinatorial use with MEK1/2 inhibitors may be a useful strategy to improve the efficacy of PI3Kδ inhibitors for B-ALL therapy, as successfully shown in other experimental cancer models [39-42]. This evidence concerns the gene MAP2K1 and acute lymphoblastic leukemia.